

ANTIPHOSPHOLIPID SYNDROME AND PREGNANCY WASTAGE

An ESSAY
Submitted for fulfillment of the Master Degree
In
Obstetrics & Gynecology

By
Mohamed Fouad Ahmed Mostafa
(M.B.B.Ch)

Supervised By

Dr. Salah Sanad
Professor of Obstetrics&Gynecology
Faculty of medicine
Cairo University

Dr. Gamal Abdel Samee
Professor of Obstetrics&Gynecology
Faculty of medicine
Cairo University

Dr. Ahmed Rezk El-Zayat
Lecturer of Obstetrics&Gynecology
Faculty of medicine
Cairo University

Faculty of medicine
Cairo University
2009

متلازمة مضادات الفوسفات الدهنية وعلاقتها بفقد الحمل

رسالة مقدمة من الطبيب

محمد فؤاد أحمد مصطفى

توطئة للحصول على درجة الماجستير

في

أمراض النساء و التوليد

تحت اشراف

أ.د/صلاح سند

أستاذ طب النساء و التوليد

بكلية الطب

جامعة القاهرة

أ.د/جمال عبد السميع

أستاذ طب النساء و التوليد

بكلية الطب

جامعة القاهرة

د/أحمد رزق الزيات

دكتورة أمراض النساء و التوليد

بكلية الطب

جامعة القاهرة

كلية الطب

جامعة القاهرة

2009

بسم الله الرحمن الرحيم

قالوا سبحانك لا علم لنا الا ما علمتنا
انك انت العليم الحكيم

صدق الله العظيم

سورة البقرة الاية (٣٢)

Index

TITLE	PAGE
Acknowledgment	vi.
Abstract	vii.
Keywords	viii.
Introduction	1
Part 1: Antiphospholipid syndrome (APS)	
1 Historical background	6
2 Pathology	9
3 Clinical manifestations	14
4 Revised criteria for diagnosis of APS	17
5 Pathogenesis of APS.	21
6 Catastrophic APS	32
7 Evidence based antithrombotic treatment of APS.	35
Part 2: APS during pregnancy	
1 Pathophysiology of APS during pregnancy.	41
2 APS and recurrent miscarriage	57
3 APS and IUGR	64
4 HELLP syndrome and APS	71
5 Treatment regimen in pregnant women with aPL.	75
6 Plasma Exchange in management of APS during pregnancy	89
7 Pharmacology of anti-thrombotic drugs during pregnancy	93
8 Prediction of APS	124
summary	129
References	133
Arabic summary	الملخص العربي

Abbreviations

AAT	alanine aminotransferase
Abs	Antibodies
ACAs	Anticardiolipin antibodies
aCL	Anticardiolipin
APASS	Antiphospholipid Antibodies and Stroke Study
APC	Activated protein C
aPL	Antiphospholipid antibodies
aPL Abs	antiphospholipid antibodies
ApoER2	Apolipoprotein E receptor 2
APS	Antiphospholipid syndrome
ARDS	acute respiratory distress syndrome
AT III	Antithrombin III
BALB/C	Type of experimental mice
CAPS	Catastrophic Antiphospholipid Syndrome
CL	cardiolipin
CMV	cytomegalovirus
FFP	fresh frozen plasma
α FII	Antiprothrombin Abs
FVa	Coagulation factor 5a (procoagulant factor)
GAGs	Glycosaminoglycans
HIT	Heparin induced thrombocytopenia
IGFBP	Insulin like growth factor binding protein
IgG	Immunoglobulin G
IgM	Immunoglobulin M
IUGR	Intra uterine growth restriction
LA	Lupus anticoagulant antibodies

LDA	Low dose aspirin
LDH	lactic dehydrogenase
LDL	Low density lipoprotein
LMWH	Low molecular weight heparin
PAF	Platelet activating factor
PAI-1	plasminogen activator inhibitor type-1
PE	Phosphatidyl ethanolamine
PGI	Prostacyclin(prostaglandin I)
PL	Phospholipid
PIC	Plasminogen inhibitor complex
PS	phosphatidylserine
PVM	Placental villous membrane
RPR	Rapid plasma regain test
RSA	recurrent spontaneous abortion
SIRS	systemic inflammatory response syndrome
SLE	systemic lupus erythematosus
β_2 -GPI	Beta 2 glycoprotein 1
$\alpha\beta_2$ -GPI	Anti- β_2 -GPI antibodies
TAT	Thrombin anti-thrombin complex
TF	Tissue factor
TLRs	Toll like receptor
tPA	Tissue plasminogen activator
TTP	Thrombotic Thrombocytopenic Purpura
UFH	Unfractionated heparin
VDRL	Venereal Disease Research Laboratories
VKAs	Vitamin k antagonists
vWf	von Willebrand factor

List of figures

NUMBER	DESCRIBE	PAGE
Figure1	Algorithm for Antithrombotic Treatment of Patients with Antiphospholipid Antibodies.	48
Figure: 2	Ultrasonic picture show Thickened and inhomogeneous placenta.	76
Figure: 3	Ultrasonic picture show Thickened and inhomogeneous placenta Lech.	76
Figure: 4	Ultrasonic picture show Thickened Hyperechogenic bowel.	77
Figure: 5	Ultrasonic picture show Thickened Hyperechogenic bowel.	77
Figure: 6	Ultrasonic picture show Thickened pulsed Doppler sonogram shows reversed A wave in the ductus venosus.	78
Figure: 7	Ultrasonic picture show Thickened pulsed Doppler sonogram shows absent end-diastolic flow in the umbilical arteries, and pulsatile flow in the umbilical vein.	78
Figure: 8	ultrasonic picture show Thickened Slight cardiomegaly with a small pericardial effusion	79
Figure: 9	Ultrasonic picture show Thickened abdominal circumference equivalent to 15+4 weeks at 19 weeks of gestational age.	79
Figure 10	Algorithm for pharmacologic treatment of women with APS during pregnancy.	95
Figure 11	Heparin molecule.	105
Figure 12	Warfarin molecule.	113
Figure 13	Aspirin molecule.	122

List of tables

NUMBER	DESCRIBE	PAGE
Table 1	Prevalence of clinical manifestations in APS patients.	25
Table 2	The nomenclature applied to antiphospholipid antibodies.	31
Table 3	Terminology for heparin regimens.	96
Table 4	Advocated heparin regimens according to different clinical situations.	97
Table 5	Blood clotting factors and drugs that affect them.	104

Acknowledgement

THANKS FOR ALLAH.

It is a pleasure to express my deepest gratitude and cordial appreciation to **Prof. Dr Salah Sanad** for his continuous encouragement, advice, support and guidance through this work.

I am greatly indebted to **Prof. Dr Gamal Abdel Samee** for his meticulous supervision, and kind guidance and valuable advice.

It is great pleasure to express my sincere appreciation and deep thanks to **Dr. Ahmed Rezk El-Zayat** for his close supervision, constant guidance and encouragement.

Abstract

This essay represents a review of the APS (antiphospholipid syndrome) and its effect on pregnancy.

It explains the pathology of APS and the effect of presence of antiphospholipid antibodies in the sera of APS patients during pregnancy

It reviews in details APS as a cause of pregnancy loss especially in first trimester. It also concentrates on management regimen of APS during pregnancy.

Keywords

APS, antiphospholipid syndrome, anticardiolipin antibodies, early pregnancy loss, miscarriage, recurrent spontaneous abortion.

بسم الله الرحمن الرحيم

**قالوا سبحانك لا علم لنا الا ما علمتنا
انك انت العليم الحكيم**

صدق الله العظيم

سورة البقرة الآية (٣٢)

ANTIPHOSPHOLIPID SYNDROME AND PREGNANCY WASTAGE

An ESSAY
Submitted for fulfillment of the Master Degree
In
Obstetrics & Gynecology

By
Mohamed Fouad Ahmed Mostafa
(M.B.B.Ch)

Supervised By

Dr. Salah Sanad
Professor of Obstetrics&Gynecology
Faculty of medicine
Cairo University

Dr. Gamal Abdel Samee
Professor of Obstetrics&Gynecology
Faculty of medicine
Cairo University

Dr. Ahmed Rezk El-Zayat
Lecturer of Obstetrics&Gynecology
Faculty of medicine
Cairo University

Faculty of medicine
Cairo University
2009

بسم الله الرحمن الرحيم

**قالوا سبحانك لا علم لنا الا ما علمتنا
انك انت العليم الحكيم**

صدق الله العظيم

سورة البقرة الآية (٣٢)

Index

TITLE	PAGE
Acknowledgment	vi.
Abstract	vii.
Keywords	viii.
Introduction	1
Part 1: Antiphospholipid syndrome (APS)	
1 Historical background	6
2 Pathology	9
3 Clinical manifestations	14
4 Revised criteria for diagnosis of APS	17
5 Pathogenesis of APS.	21
6 Catastrophic APS	32
7 Evidence based antithrombotic treatment of APS.	35
Part 2: APS during pregnancy	
1 Pathophysiology of APS during pregnancy.	41
2 APS and recurrent miscarriage	57
3 APS and IUGR	64
4 HELLP syndrome and APS	71
5 Treatment regimen in pregnant women with aPL.	75
6 Plasma Exchange in management of APS during pregnancy	89
7 Pharmacology of anti-thrombotic drugs during pregnancy	93
8 Prediction of APS	124
summary	129
References	133
Arabic summary	الملخص العربي